These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 35202771)

  • 21. Effect of SGLT-2 Inhibitors on Non-alcoholic Fatty Liver Disease among Patients with Type 2 Diabetes Mellitus: Systematic Review with Meta-analysis and Trial Sequential Analysis of Randomized Clinical Trials.
    Lee KW; Devaraj NK; Ching SM; Veettil SK; Hoo FK; Deuraseh I; Soo MJ
    Oman Med J; 2021 May; 36(3):e273. PubMed ID: 34239714
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Correlation analysis of gut microbiota and biochemical indexes in patients with non-alcoholic fatty liver disease].
    Ren SM; Mei L; Huang H; Cao SF; Zhao RH; Zheng PY
    Zhonghua Gan Zang Bing Za Zhi; 2019 May; 27(5):369-375. PubMed ID: 31177662
    [No Abstract]   [Full Text] [Related]  

  • 23. Dapagliflozin improves steatohepatitis in diabetic rats via inhibition of oxidative stress and inflammation.
    Hazem RM; Ibrahim AZ; Ali DA; Moustafa YM
    Int Immunopharmacol; 2022 Mar; 104():108503. PubMed ID: 34998036
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dietary Interventions in Patients With Non-alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis.
    Houttu V; Csader S; Nieuwdorp M; Holleboom AG; Schwab U
    Front Nutr; 2021; 8():716783. PubMed ID: 34368214
    [No Abstract]   [Full Text] [Related]  

  • 25. Efficacy and safety of Huazhi Rougan granule in the treatment of non-alcoholic fatty liver: a systematic review and meta-analysis.
    Wang T; Song J; Hu J; Feng S; Zhang H; Wang H; Li B
    Ann Palliat Med; 2021 Dec; 10(12):12969-12984. PubMed ID: 33691456
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of dapagliflozin on obstructive sleep apnea in patients with type 2 diabetes: a preliminary study.
    Tang Y; Sun Q; Bai XY; Zhou YF; Zhou QL; Zhang M
    Nutr Diabetes; 2019 Nov; 9(1):32. PubMed ID: 31685792
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of pentoxifylline on nonalcoholic fatty liver disease: a meta-analysis.
    Du J; Ma YY; Yu CH; Li YM
    World J Gastroenterol; 2014 Jan; 20(2):569-77. PubMed ID: 24574727
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of Empagliflozin on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial (E-LIFT Trial).
    Kuchay MS; Krishan S; Mishra SK; Farooqui KJ; Singh MK; Wasir JS; Bansal B; Kaur P; Jevalikar G; Gill HK; Choudhary NS; Mithal A
    Diabetes Care; 2018 Aug; 41(8):1801-1808. PubMed ID: 29895557
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of Dapagliflozin on Glycemic Control, Weight, and Blood Pressure in Patients with Type 2 Diabetes Attending a Specialist Endocrinology Practice in Canada: A Retrospective Cohort Analysis.
    Brown RE; Gupta N; Aronson R
    Diabetes Technol Ther; 2017 Nov; 19(11):685-691. PubMed ID: 28829163
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of probiotics on nonalcoholic fatty liver disease: a meta-analysis.
    Ma YY; Li L; Yu CH; Shen Z; Chen LH; Li YM
    World J Gastroenterol; 2013 Oct; 19(40):6911-8. PubMed ID: 24187469
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Acupoint embedding therapy improves nonalcoholic fatty liver disease with abnormal transaminase: A PRISMA-compliant systematic review and meta-analysis.
    Dai L; Ooi VV; Zhou W; Ji G
    Medicine (Baltimore); 2020 Jan; 99(3):e18775. PubMed ID: 32011470
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Irisin in patients with nonalcoholic fatty liver disease.
    Polyzos SA; Kountouras J; Anastasilakis AD; Geladari EV; Mantzoros CS
    Metabolism; 2014 Feb; 63(2):207-17. PubMed ID: 24140091
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of HuoXueHuaYu therapy for nonalcoholic fatty liver disease: a systematic review and meta-analysis of randomized controlled trial.
    Cai Y; Liang Q; Chen W; Chen M; Chen R; Zhang Y; Xiao Y; Chen L
    BMC Complement Altern Med; 2019 Jul; 19(1):178. PubMed ID: 31324247
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Effect of Low Glycemic Index and Glycemic Load Diets on Hepatic Fat Mass, Insulin Resistance, and Blood Lipid Panels in Individuals with Nonalcoholic Fatty Liver Disease.
    Parker A; Kim Y
    Metab Syndr Relat Disord; 2019 Oct; 17(8):389-396. PubMed ID: 31305201
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dapagliflozin in patients with type II diabetes mellitus, with and without elevated triglyceride and reduced high-density lipoprotein cholesterol levels.
    Bays HE; Sartipy P; Xu J; Sjöström CD; Underberg JA
    J Clin Lipidol; 2017; 11(2):450-458.e1. PubMed ID: 28502502
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and Safety of GLP-1 Receptor Agonists in Patients With Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis.
    Zhu Y; Xu J; Zhang D; Mu X; Shi Y; Chen S; Wu Z; Li S
    Front Endocrinol (Lausanne); 2021; 12():769069. PubMed ID: 34956080
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of dapagliflozin and/or insulin glargine on beta cell mass and hepatic steatosis in db/db mice.
    Omori K; Nakamura A; Miyoshi H; Takahashi K; Kitao N; Nomoto H; Kameda H; Cho KY; Takagi R; Hatanaka KC; Terauchi Y; Atsumi T
    Metabolism; 2019 Sep; 98():27-36. PubMed ID: 31202833
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Green tea as a safe alternative approach for nonalcoholic fatty liver treatment: A systematic review and meta-analysis of clinical trials.
    Mansour-Ghanaei F; Hadi A; Pourmasoumi M; Joukar F; Golpour S; Najafgholizadeh A
    Phytother Res; 2018 Oct; 32(10):1876-1884. PubMed ID: 29947156
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term empagliflozin therapy improves levels of hepatic fibrosis marker in patients with non-alcoholic fatty liver disease complicated by type 2 diabetes mellitus.
    Shinozaki S; Tahara T; Lefor AK; Ogura M
    J Med Invest; 2020; 67(3.4):280-284. PubMed ID: 33148902
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of omega-3 fatty acids on liver-related outcomes in patients with nonalcoholic fatty liver disease: A protocol for a systematic review and meta-analysis.
    Shi XY; Fan SM; Shi GM; Yao J; Gao Y; Xia YG; Chen Q
    Medicine (Baltimore); 2020 Jun; 99(24):e20624. PubMed ID: 32541499
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.